Inhaled Nitric Oxide Market By Product Type (Inhaled Nitric Oxide Delivery Systems, Inhaled Nitric Oxide Gas), By Application (Neonatal Care, Acute Respiratory Distress Syndrome, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease, Other Respiratory Disorders), By End-User Industry (Hospitals, Ambulatory Surgical Centers, Homecare Settings), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Inhaled Nitric Oxide Market was valued at USD 0.7 Billion in 2024-e and will surpass USD 1.1 Billion by 2030; growing at a CAGR of 7.4% during 2025-2030.

The Inhaled Nitric Oxide (iNO) market has been witnessing substantial growth driven by increasing awareness regarding its therapeutic benefits, particularly for respiratory disorders. The market is characterized by a range of applications in medical settings such as neonatal care, treatment of pulmonary hypertension, and management of conditions like Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD). Inhaled nitric oxide serves as an essential therapeutic gas in improving oxygenation and pulmonary function, making it a key element in critical care, especially in neonatal and respiratory support units. The market's trajectory is further propelled by rising healthcare expenditure, advancements in medical technologies, and increasing incidences of chronic respiratory diseases worldwide.

Product Type: Inhaled Nitric Oxide Delivery Systems Is Largest Owing to Their Key Role in Treatment Delivery

The Inhaled Nitric Oxide Delivery Systems segment is the largest in the iNO market, owing to the essential role these systems play in the effective administration of nitric oxide for medical purposes. These systems are primarily used in hospital settings for conditions such as neonatal pulmonary hypertension, ARDS, and other acute pulmonary disorders. They deliver precise concentrations of nitric oxide to the patient, which helps relax and dilate pulmonary blood vessels, reducing pulmonary hypertension and improving oxygenation. As the primary method of administering nitric oxide therapy, these delivery systems are integral to achieving desired patient outcomes, contributing to their dominance in the market.

The advancements in inhaled nitric oxide delivery systems also play a significant role in this segment's growth. The development of portable and user-friendly delivery devices, which enhance patient comfort and mobility, has further bolstered the adoption of these systems. As healthcare providers continue to prioritize precise, efficient, and effective treatment methods, the demand for these systems is expected to continue growing, maintaining their position as the largest subsegment in the market.

Application: Neonatal Care Is Largest Owing to Rising Demand for Respiratory Support in Newborns

Neonatal Care remains the largest application segment in the inhaled nitric oxide market. Neonatal care represents a significant portion of the market due to the increasing number of preterm births and cases of persistent pulmonary hypertension of the newborn (PPHN). Nitric oxide therapy has proven to be highly effective in treating PPHN, a condition where the newborn's lungs are unable to provide enough oxygen to the body, leading to increased pulmonary pressure. Inhaled nitric oxide relaxes blood vessels in the lungs, improving blood flow and oxygenation, which is critical for the survival of neonates in critical care units.

As neonatal intensive care units (NICUs) continue to be equipped with advanced technologies for treating premature infants and newborns with respiratory complications, the demand for inhaled nitric oxide in these settings is growing. This is especially true in emerging markets where neonatal care infrastructure is improving, and healthcare services are becoming more accessible. The proven effectiveness and life-saving capabilities of inhaled nitric oxide in neonatal care solidify its dominance in this application segment.

End-User: Hospitals Are Largest End-User Owing to High Demand for Critical Care Treatments

Hospitals represent the largest end-user segment in the inhaled nitric oxide market. Hospitals are key consumers of inhaled nitric oxide therapy due to the growing prevalence of respiratory disorders such as pulmonary hypertension, ARDS, and chronic obstructive pulmonary disease (COPD). The critical care departments, particularly neonatal intensive care units (NICUs) and intensive care units (ICUs), make extensive use of inhaled nitric oxide to treat patients suffering from acute and chronic respiratory conditions. This is in response to the need for better management of oxygenation levels, pulmonary function, and reducing the reliance on mechanical ventilation.

The growing incidence of respiratory diseases worldwide and the increasing adoption of advanced treatment options in hospital settings are significant drivers for the adoption of inhaled nitric oxide. Hospitals offer the most comprehensive resources for administering such treatments, with the necessary medical staff, monitoring systems, and equipment to ensure patient safety and efficacy. As healthcare systems worldwide continue to emphasize critical care and respiratory support, hospitals are expected to remain the dominant end-user of inhaled nitric oxide.

Region: North America Is Largest Region Owing to Advanced Healthcare Infrastructure and High Disease Prevalence

North America is the largest region in the inhaled nitric oxide market, driven by the presence of advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and a strong prevalence of respiratory diseases. The U.S., in particular, leads the market due to its well-established healthcare system, increasing incidence of respiratory disorders such as COPD and pulmonary hypertension, and the high demand for neonatal care services. The region's focus on improving neonatal outcomes, combined with high levels of healthcare spending, has created a favorable environment for the widespread use of inhaled nitric oxide in clinical settings.

Furthermore, North America's regulatory framework and healthcare policies support the growth of the iNO market, encouraging the adoption of innovative therapeutic treatments in hospitals and clinics. As healthcare providers and institutions in the region continue to prioritize advanced respiratory therapies, North America will maintain its position as the largest market for inhaled nitric oxide.

Competitive Landscape: Leading Companies Drive Innovation in Inhaled Nitric Oxide Technologies

The competitive landscape in the inhaled nitric oxide market is characterized by a mix of well-established companies and emerging players focused on delivering innovative medical gases and delivery systems. Mallinckrodt Pharmaceuticals, Praxair Technology, Linde Group, and Drägerwerk AG are the leading players in the market, with a strong presence in both the production of nitric oxide gas and the development of delivery systems for medical use. These companies are constantly investing in research and development to improve the safety, efficiency, and delivery of inhaled nitric oxide therapies.

The competitive landscape is also shaped by partnerships and collaborations between healthcare providers, research institutions, and medical device manufacturers, aiming to enhance the accessibility and affordability of nitric oxide therapy. Additionally, companies are focusing on expanding their product portfolios and addressing unmet needs in neonatal care, critical care, and pulmonary hypertension. As the demand for advanced respiratory therapies grows globally, companies in the inhaled nitric oxide market will continue to innovate and evolve to stay competitive in this expanding industry.

List of Leading Companies:

• Mallinckrodt Pharmaceuticals
• Praxair Technology
• Linde Group
• Air Products and Chemicals, Inc.
• Merck & Co., Inc.
• Siemens Healthineers
• Drägerwerk AG & Co. KGaA
• Inhaled Nitric Oxide Company, Inc.
• VitalAire
• West Pharmaceutical Services
• GE Healthcare
• Fisher & Paykel Healthcare
• Abbott Laboratories
• Medtronic
• ResMed

Recent Developments:

• Mallinckrodt Pharmaceuticals announced a new study demonstrating the effectiveness of their inhaled nitric oxide product in treating neonatal pulmonary hypertension, reinforcing its position in the market.
• Praxair Technology launched a new portable inhaled nitric oxide delivery system, designed to improve patient mobility and comfort while delivering the necessary therapeutic gas for respiratory treatment.
• Linde Group expanded its production of medical gases, including inhaled nitric oxide, to meet the growing demand in hospitals and homecare settings across Europe and North America.
• Drägerwerk AG received regulatory approval for its new inhaled nitric oxide therapy device, which aims to improve the delivery and monitoring of nitric oxide therapy for patients with severe pulmonary conditions.
• Siemens Healthineers entered into a partnership with a leading hospital chain to provide integrated inhaled nitric oxide treatment solutions, enhancing its healthcare portfolio and patient care services.

Report Scope: